You can buy or sell Novan and other stocks, options, ETFs, and crypto commission-free!
Novan, Inc. Common Stock, also called Novan, is a biotechnology company which uses nitric oxide-based technology to develop product candidates. Read More It focuses on nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.
Morrisville, North Carolina
52 Week High
52 Week Low
Associated PressMar 19
Novan and Sato Advance Japan Market and Dermatology Partnership
-- Dr. Elizabeth Messersmith named chairperson of the Sato and Novan Joint Committee -- Simultaneous clinical development progress for SB206 in Japan and US underway -- Novan receives second installment of $4.5 million under the SB206 Japan license agreement MORRISVILLE, N.C., March 19, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has named Dr. Elizabeth Messersmith, the Company’s Senior Vice President and Chief Development Officer, the chai...
VTX:NOVN - Stock Price, News, & Analysis for Novartis
Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for t...
PR NewswireFeb 26
KNOW Bio Announces Creation of Digestive Health Therapeutics, Inc.
DURHAM, N.C., Feb. 26, 2019 /PRNewswire/ -- KNOW Bio, LLC., (the Company), a North Carolina developer of nitric oxide-based medical technology and related biotechnology companies, announced today that the Company has formed a new wholly-owned operating subsidiary, Digestive Health Therapeutics, Inc, to develop the Company's technology in the field of gastroenterology. Dr. Mark Schoenfisch, inventor of the enabling technology and KNOW Bio Director stated, "Nitric oxide is a cellular messenger with important...
-$0.31 per share
Expected Mar 27, Pre-Market